VSTM — Verastem, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1526119 ·
Last close
$8.11
Market Cap
$734.47M
52W High
$10.82
52W Low
$3.43
ADV30
2,436,737
Next earnings
2026-11-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 40,078,000 | 36,037,000 | -32,710,000 | -34,673,000 | 206,511,000 | 136,353,000 | 156,525,000 |
| Mar 2026 | 18,671,000 | 15,620,000 | -44,897,000 | -36,591,000 | 227,808,000 | 165,551,000 | 146,031,000 |
| Dec 2025 | 17,535,000 | 14,643,000 | -41,475,000 | -32,916,000 | 246,442,000 | 204,990,000 | 189,245,000 |
| Sep 2025 | 11,242,000 | 9,282,000 | -40,715,000 | -98,518,000 | 176,852,000 | 137,706,000 | 192,378,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-162,195,000
Investing CF
$-9,389,000
Financing CF
$143,615,000
CapEx
$-1,345,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.78
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,236,262,000
Inventory
$2,396,000
Receivables
$29,074,000
ST Investments
$16,127,000
EBIT TTM
$-200,406,000
Pretax Income TTM
$-201,882,000
Interest Exp TTM
$1,476,000
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$87,526,000
EBITDA
$-158,647,008
Free Cash Flow
$-103,429,624
Enterprise Value
$610,901,376
Total Cash
$136,352,992
Total Debt
$84,330,000
Shares Out
90,563,441
Trailing EPS
$-2.44
Book Value
$0.93
ROE
-471.2%
ROA
-49.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 30,914,000 | -170,129,000 | -209,471,000 | 246,442,000 | 189,245,000 | 57,197,000 | -137,509,000 |
| Dec 2024 | 10,000,000 | -114,956,000 | -130,637,000 | 101,538,000 | 130,431,000 | -28,893,000 | -104,771,000 |
| Dec 2023 | 0 | -92,084,000 | -87,367,000 | 149,718,000 | 92,344,000 | 57,374,000 | -86,460,000 |
| Dec 2022 | 2,596,000 | -72,937,000 | -73,812,000 | 95,050,000 | 47,659,000 | 47,391,000 | -63,673,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$48,625,000
NetIncome TTM
$-193,959,000
OpCashFlow TTM
—
Assets (Latest)
$227,808,000
Forward EPS
$-0.75
Max Pain — expiry 2026-10-16
max pain strike: $8.00 · spot: $8.38 · call oi: 5,100 · put oi: 1,171
Expected Move to 2026-10-16:
±$2.85
(34.01%) —
implied range
$5.53 –
$11.23
· ATM straddle on $8.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SLNCF | Silence Therapeutics plc | $745.85M | $4.00 | — |
| AVTX | Avalo Therapeutics, Inc. | $720.25M | $13.43 | — |
| DSGN | Design Therapeutics, Inc. | $719.06M | $11.49 | — |
| GYRE | GYRE THERAPEUTICS, INC. | $716.79M | $6.76 | — |
| OBX | Obsidian Therapeutics, Inc. | $756.10M | $12.24 | — |
News headlines (Yahoo Finance, 1h cache)
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-10-05 20:02 · Yahoo
Verastem Oncology Announces New RAMP 201 Molecular Profiling and External Control Arm Analyses Describing Outcomes for Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be P
2026-10-02 11:30 · Yahoo
Verastem Oncology Announces Publication in Gynecologic Oncology of Two-Year Median Follow-Up Data from RAMP 201 Study of AVMAPKI® FAKZYNJA® CO-PACK (avutometinib capsules; defactinib tablets) in Recur
2026-09-28 20:10 · Yahoo
Verastem Oncology Announces Late-Breaking Oral Presentation of RAMP 201 Low-Grade Serous Ovarian Cancer Molecular Profiling and Tumor Biomarker Analysis at IGCS 2026 Annual Global Meeting
2026-09-24 12:30 · Yahoo
Verastem Stock Skyrockets 121% in 3 Months: Here Is Why
2026-09-08 14:09 · Yahoo
Verastem Oncology to Participate in Upcoming September Investor Conferences
2026-09-02 11:30 · Yahoo
Verastem (VSTM) Stock Sees Fair Value Moves Lower As Analysts Cut Revenue Views
2026-08-25 18:17 · Yahoo
Verastem (VSTM) Q2 2026 Earnings Call Transcript
2026-08-13 23:46 · Yahoo
Verastem Q2 Earnings Call Highlights
2026-08-07 20:04 · Yahoo
Verastem Inc (VSTM) (Q2 2026) Earnings Call Highlights: Strong Revenue Rebound and Strategic ...
2026-08-07 05:10 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.